Exchange: NASDAQ·Updated 12:58 PM EDT

AACPApogee Acquisition Corp. - Ordinary Shares - Class A

$9.98
$0.00
(0.00%)
Today
Mkt Cap$57.33M
Vol606.00
News
all
press releases
News Placeholder
AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst
AbbVie will acquire Apogee Therapeutics for $10.9 billion, with analyst citing long-term immunology growth despite near-term dilution.read more...
Benzinga
<
...
1
>
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.